Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2007-03-27
2007-03-27
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S185100, C424S188100, C424S208100, C530S326000, C530S300000, C530S324000, C530S325000, C530S826000
Reexamination Certificate
active
10373592
ABSTRACT:
The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.
REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5352576 (1994-10-01), Haynes et al.
patent: 5516632 (1996-05-01), Palker et al.
patent: 5643756 (1997-07-01), Kayman et al.
patent: 5800822 (1998-09-01), Sia et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 6114143 (2000-09-01), Eda et al.
patent: 2001/0003646 (2001-06-01), Haynes et al.
patent: 2001/0036461 (2001-11-01), Haynes et al.
patent: 2002/0086283 (2002-07-01), Haynes et al.
patent: 2003/0147888 (2003-08-01), Haynes et al.
patent: 2004/0039172 (2004-02-01), Haynes et al.
patent: 2004/0086506 (2004-05-01), Haynes et al.
patent: 2004/0132010 (2004-07-01), Haynes et al.
patent: 2004/0197344 (2004-10-01), Haynes et al.
patent: WO 93/15750 (1993-08-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 97/14436 (1997-04-01), None
patent: WO 01/56355 (2001-08-01), None
patent: WO 02/24149 (2002-03-01), None
patent: WO 03/039470 (2003-05-01), None
patent: WO 03/046137 (2003-06-01), None
patent: WO 2004/009785 (2004-01-01), None
patent: WO 2004/075850 (2004-09-01), None
patent: WO 2005/016952 (2005-02-01), None
Haynes et al, HIV Vaccine Development at Duke University Medical Center, Immunologic Research 22(2-3):263-269 (2000).
Bartlett et al, “Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen”, AIDS 12(11):1291-1300 (1998).
De Berardinis et al, “Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses”, Nature Biotechology 18:873-876 (2000).
U.S. Appl. No. 60/503,460 filed Sep. 17, 2003 and U.S. Appl. No. 60/604,722 filed Aug. 27, 2004 (see attached copy of PCT/US04/30397 filed Sep. 17, 2004).
U.S. Appl. No. 10/518,523 filed Dec. 21, 2004 (U.S National Phase of WO 2004/009785 see above).
U.S. Appl. No. 10/973,977 filed Oct. 27, 2004.
U.S. Appl. No. 10/973,475 filed Oct. 27, 2004.
U.S. Appl. No. 60/625,720 filed Nov. 8, 2004.
Pang et al, “HIV-1EnvSequence Variation in Brain Tissue of Patients with AIDS-Related Neurologic Disease”. Journal of Acquired Immune Deficiency Syndrome 4:1082-1092 (1991).
De Lorimier Robert M.
Haynes Barton F.
Korber Bette T.
Duke University
Nixon & Vanderhye P.C.
Stucker Jeffrey
The Regents of the University of California
LandOfFree
Polyvalent immunogen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyvalent immunogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyvalent immunogen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3800361